Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment

TY - JOUR

T1 - Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment

AU - Rustgi, Vinod

PY - 2004/12

Y1 - 2004/12

N2 - The worldwide spread of hepatitis C virus is enormous; chronic hepatitis C virus infection is a leading cause of liver cirrhosis and hepatocellular carcinoma. While treatment options have improved substantially over the last decade, responses are still disappointing, particularly in certain difficult-to-treat groups such as patients who are immunosuppressed or have decompensated disease. Preliminary studies have indicated that combined treatment strategies may provide effective approaches for the future. The combination of thymalfasin with pegylated interferon is currently a promising option for the treatment of patients with chronic hepatitis C virus infection. An ongoing phase 3 study in the USA should provide much needed data to improve the outcome for these patients.

AB - The worldwide spread of hepatitis C virus is enormous; chronic hepatitis C virus infection is a leading cause of liver cirrhosis and hepatocellular carcinoma. While treatment options have improved substantially over the last decade, responses are still disappointing, particularly in certain difficult-to-treat groups such as patients who are immunosuppressed or have decompensated disease. Preliminary studies have indicated that combined treatment strategies may provide effective approaches for the future. The combination of thymalfasin with pegylated interferon is currently a promising option for the treatment of patients with chronic hepatitis C virus infection. An ongoing phase 3 study in the USA should provide much needed data to improve the outcome for these patients.

KW - Chronic hepatitis C virus

KW - Combination treatment

KW - Peginterferon alfa-2a

KW - Thymalfasin

UR - http://www.scopus.com/inward/record.url?scp=11144220015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144220015&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/j.1400-1746.2004.03632.x

DO - https://doi.org/10.1111/j.1400-1746.2004.03632.x

M3 - Article

C2 - 15546255

SN - 0815-9319

VL - 19

SP - S76-S78

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

IS - 12

ER -